Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3a and C3b), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3a (C3a1 and a2), and C3b that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3a (C3a1 and a2) and C3b. Amino acids mapping to C3a and C3f are absent. Taken together, the C3a and C3b amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the
I N T R O D U C T I O N
C3 glomerulopathy (C3G) is characterized by glomerular deposits of C3 with minimal or no immunoglobulin (Ig) deposits, a finding consistent with the underlying pathogenesis of the disease, i.e. overactivation of the alternative pathway (AP) of the complement system [1] [2] [3] [4] [5] [6] . Electron microscopic differences are used to subdivide C3G into two broad subgroups, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD) [3] . The former is characterized by mesangial and subendothelial, intramembranous and sometimes subepithelial capillary wall deposits, while in the latter, the deposits are dense, osmiophilic, sausage-shaped intramembranous and mesangial [7, 8] .
In earlier studies using laser microdissection and liquid chromatography-mass spectrometry (LC-MS), we have shown that in both C3GN and DDD, there is pronounced glomerular accumulation of complement components C3, C5, C6, C7, C8 and C9, with C3 being the most predominant [2, 9] . C3 is a large protein encoded by the C3 gene on chromosome 19 that plays a central role in the complement cascade and is required for normal complement activity. Its proteolytic cleavage generates C3a and C3b. The former is an anaphylotoxin and a precursor for cytokines, while the latter is an opsonizing agent with a reactive thioester to facilitate its covalent binding to primary amine or hydroxyl nucleophiles on cell surfaces, circulating proteins and the glycocalyx, the glycoprotein-polysaccharide fuzzy covering on the external surface of cells and exposed basement membranes such as the glomerular basement membrane (GBM). 
LC-MS in six cases of C3GN and six cases of DDD to define the composition of the C3 fragments.
M A T E R I A L S A N D M E T H O D S
Renal biopsies from six C3GN and six DDD patients were evaluated [2, 9, 10] . In all cases, routine workup including light, immunofluorescence and electron microscopy was performed. Clinical information was obtained from the charts. The Institutional Review Board at the Mayo Clinic approved this study. For detection of C3 by immunofluorescence studies, polyclonal fluorescein isothiocyanate (FITC)-labeled anti-human C3c antibody (Dako) was used.
Specimen preparation, LC-MS proteomic analysis
The methods have been published previously [9, 11] . Briefly, for each case, a 10-lm-thick section of formalin-fixed paraffinembedded tissue was mounted on a Director slide, stained with hematoxylin and eosin and laser microdissection (LMD) was performed by collecting 100 000 lm 2 glomeruli per slide and studying three separate dissections per case. The LMD material was collected in 35 mL of Tris/EDTA/0.002% Zwittergent buffer. Microdissected fragments were digested into peptides using trypsin and analyzed on either an LTQ-Velos or an LTQOrbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) using liquid chromatography-assisted tandem mass spectrometry (LC-MS/MS). Peptides present in the raw data files were identified using three different search engines (Sequest [12] , Mascot [13] and X!Tandem [14] ). The search engines were configured to match the spectra to peptides derived from the SwissProt human database (downloaded July 2012). Decoy sequences were appended to the database to estimate the peptide and protein false discovery rates [15] . Scaffold software (Proteome Software, Portland, OR, USA) combined the results and assembled the proteins into peptides [16] . For each case, we generated a list of proteins identified in each dissection. Proteins with at least two confident (probability >90%) peptide identifications were considered to be present in a dissection. Proteins with at least four MS/MS spectral counts were considered for clinical interpretation. The number of MS/MS spectra assigned to a protein is considered as a semiquantitative measure of its abundance. Proteins with higher spectral counts are of greater abundance when compared with proteins with lower spectral counts and they typically yield greater amino acid sequence coverage. In other words, greater amino acid sequence coverage represents greater abundance of the protein [17, 18] . The percentage amino acid coverage was calculated by the number of amino acids detected divided by the total number of amino acids in the sequence of the particular C3 fragment.
R E S U L T S

Patient characteristics and renal biopsy results
Renal biopsies from 12 patients ranging in age from 11 to 61 years with C3GN or DDD were selected for this study.
Hematuria and proteinuria were present in all patients. Five patients had stable renal function at the time of presentation (Table 1) . On light microscopy, renal biopsy revealed a membranoproliferative pattern of injury in 10 patients, severe crescentic glomerulonephritis in 1 patient and diffuse proliferative glomerulonephritis with few crescents in 1 patient; one biopsy also showed extensive segmental glomerulosclerosis. By immunofluorescence, all cases showed bright C3 deposition in the mesangium and along the glomerular capillary walls, with two biopsies showing trace to 1þ for IgM and one biopsy showing trace IgG staining. The remaining nine biopsies were negative for all IgGs, including IgA, IgG, IgM, C1q, kappa, and lambda light chains. All C3GN had numerous mesangial and subendothelial electron dense deposits by electron microscopy, with subepithelial deposits also present in four cases. All DDD cases showed numerous dense mesangial and intramembranous deposits. Representative findings from a biopsy of C3GN (Patient 8, top panel) and DDD (Patient 11, bottom panel) are shown in Figure 1 .
Laser microdissection and mass spectrometry
Only preserved glomeruli were selected for microdissection, as global glomerulosclerosis precludes a meaningful readout. Representative glomeruli before and after dissection are shown in Figure 2 . Factor H-related proteins (CFHR) 1 and 5 were also present, with higher spectral counts of CFHR1 compared with CFHR5. Smaller spectra numbers of C6, C7 and C8 were seen in both C3GN and DDD. LC-MS of control time 0 protocol biopsies (five cases) did not reveal any complement factors.
Characterization of C3 spectra detected by LC-MS
All patients showed extensive overall amino acid sequence coverage of C3 ranging from 4.3 to 23% (average 12%, see Supplementary Figure) . Amino acids detected by LC-MS were mapped onto C3 to identify the various fragments retrieved by LC-MS (Table 2 and Figure 4 ). The dominant C3 signature was from amino acids in the C3dg fragment, which contains the thioester domain, and was seen in all cases. The percentage amino acid coverage of C3dg ranged from 15.4 to 50% (average 30.7%, see Supplementary Figure) , with higher amino acid sequence coverage representing greater abundance of the protein. Interestingly, there was no significant difference in the C3dg amino acid sequence coverage between C3GN (32.9%) and DDD (28.6%). The remaining amino acids were present in much lesser abundance and mapped to C3a1 (average 6.5%, range 4.3-14.5%), C3a2 (average 6.5%, range 3.5-17.5%) and C3b (average 7.3%, range 2.2-17.8%) and were identified in both C3GN and DDD cases. Amino acids belonging to the heptadecapeptide C3f and the 77 amino acid C3a fragments were not detected in any of the cases.
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The AP of complement is unique as an initiating pathway of complement because of low-level constitutive activity driven by the slow spontaneous hydrolysis of the labile thioester bond of C3. This 'tick-over' hydrolysis generates an active 'C3b-like' C3 that binds factor B to assemble C3(H 2 O)Bb convertase, which by cleaving C3 generates the metastable C3b and thereafter C3bBb. Although fluid-phase convertase activity of C3bBb is Representative kidney biopsy findings in C3 glomerulopathy. C3 glomerulonephritis (Patient 8) with (A) a membranoproliferative proliferative pattern of injury on light microscopy (hematoxylin and eosin stain, Â20), (B) bright mesangial and capillary wall C3 staining on immunofluorescence microscopy (Â40) and (C) numerous mesangial and capillary wall deposits on electron microscopy (Â4000). DDD (Patient 11) with (D) membranoproliferative proliferative pattern of injury on light microscopy (periodic acid-Schiff stain, Â40), (E) bright mesangial and capillary wall C3 staining on immunofluorescence microscopy (Â40) and (F) dense deposits along the capillary walls on electron microscopy (Â4200).
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about twice that of C3(H 2 O)Bb, in a matter of seconds both convertases are inactivated by factor H and factor I, thereby preventing deregulation of the complement cascade. In C3G, the half-life of C3bBb is extended by either circulating autoantibodies to C3bBb that interfere with normal control mechanisms, gain-of-function mutations in complement activator genes (e.g. C3 and CFB) or loss-of-function mutations in complement regulator genes (e.g. CFH and CFHRs). The proteolytic cleavage of C3 to C3b therefore continues unchecked, leading to massive consumption of C3 with the generation of massive amounts of C3b ( Figure 5 ). Generation of C3b results in exposure of the unstable thioester bond in C3b that reacts very quickly with available amine or hydroxyl groups to covalently attach C3b on neighboring surfaces and proteins in a FIGURE 3: Complement profile in C3GN and DDD. Representative scaffold readout of proteins of interest from the 12 patients showing the highest spectra numbers for C3, followed by C9 and C5. Smaller spectra numbers of C8, C6 and C7 are also present. All cases also showed large spectra numbers for CFHR1, and six cases also showed smaller spectra numbers of CFHR5. Yellow stars indicate proteins of interest while the blue star indicates the protein with the highest spectra number. 
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random and inefficient process. In the hemoconcentrated microenvironment of the glomerulus, the glycomatrix overlying the endothelial cell surface and the exposed GBM is decorated with bound C3b via the thioester bond. Once bound, C3b must be either inactivated or alternatively, in a chain-reaction-like amplification process, more C3b molecules can attach, resulting in activation of the cytolytic pathway of complement. In C3G, the fate and composition of the attached C3 is unclear.
Inactivation of C3b is driven by a family of proteins called regulators of complement activation (RCA). Glomerular Percentage amino acid coverage was calculated by the number of C3 amino acids detected divided by the total number of amino acids in C3. A total of 323 amino acids were detected out of 1663 amino acids for an overall 19% coverage, with 27 unique peptides and a total of 79 spectra with 35 unique spectra. (B) A total of 249 amino acids were detected out of 1663 amino acids for an overall 15% coverage, with 18 unique peptides and a total of 25 spectra with 24 unique spectra. The sequences shown are as follows: before red bar ¼ signal sequence, between two red bars ¼ b chain, between two black bars ¼ C3a, between second black and first blue ¼ C3ca1, between blue bars ¼ C3dg, between second blue and green bar ¼ C3f, from green to end ¼ C3ca2. Amino acids detected by mass spectrometry analysis are highlighted in yellow; green highlight shows oxidized or methylated amino acids.
endothelial cells express three surface-bound RCA proteinsmembrane cofactor protein (MCP), decay-accelerating factor (DAF) and CD59. Both MCP (CD46) and DAF (CD55) are structurally similar. Each is comprised of four N-terminal extracellular short consensus repeat units followed by a short heavily glycosylated stalk and either a transmembrane domain (MCP) or a lycosylphosphatidylinositol anchor (DAF). MCP regulates complement by binding C3b (and C4b) and acting as a cofactor for factor I-mediated proteolytic cleavage of C3b to iC3b ( Figure 5 ) with the release of C3f. If, however, prior to C3b inactivation, C3bBb forms, DAF mediates its decay (but not that of its inactive proenzyme, C3bB) thereby preventing further C3b generation and deposition. Should complement activity 'escape' these two regulators, CD59 prevents the formation of membrane attack complex (MAC). This 77 amino acid glycoprotein binds C8 and/or C9, thereby preventing the incorporation of multiple copies of C9 into MAC, a necessary prerequisite for osmolytic pore formation. Although none of these RCA proteins is present in the endothelial pores to inactivate covalently bound C3b, it is unlikely that large amounts of C3bBb are formed since factor B spectra are notably absent from all C3G samples. This finding suggests that the fate of glycocalyx-bound C3b is its inactivation by cleavage, with the identified spectra reflecting the proportional distribution of the various C3 fragments-greater coverage implies a higher concentration of that specific detected portion of C3 [17] . For example, the 77 amino acid C3a fragment (9 kDa) was not present in any sample, excluding passive entrapment of intact C3. Neither did we see the heptadecapeptide C3f (2 kDa) in any sample, which is the first fragment released in the sequential cleavage of C3b. Its small size, however, precludes meaningful conclusions from this observation.
The most abundant C3 fragment detected was C3dg, which was identified in all C3G cases. Although C3dg is only 349 amino acids, this finding reflects the ultimate fate of the factor I-mediated cleavage process of C3b, which culminates with the release of C3c into the fluid phase and the persistent attachment of C3dg by its anchoring thioester. Excluding the C3dg spectra, the remaining spectra mapped to C3a (C3a1 and C3a2) and C3b, and were identified in both C3GN and DDD cases. These spectra represent iC3b prior to cleavage, a germane observation for two reasons. First, the only known cofactor for the factor Imediated cleavage of iC3b to C3c and C3dg is CR1, a membrane-bound regulator of complement that is not expressed on glomerular endothelial cells, although it is expressed on podocytes. Second, in addition to factor H, spectra for CFHR1 and 5 were also present, with spectral counts of CFHR1 being higher in C3GN when compared with DDD. This finding is noteworthy, as there is compelling evidence that FHR proteins are essential regulators of complement in the glomerular microenvironment. Normally, FHR1, FHR2 and FHR5 circulate in plasma as a combinatorial repertoire of oligomeric complexes that includes FHR1, FHR2 and FHR5 homodimers and FHR1-FHR2 and FHR1-FHR5 heterodimers. How they control complement and facilitate the cleavage of iC3b is not clear at this time.
It is also noteworthy that routine evaluation for C3 by immunofluorescence studies uses FITC-labeled antibodies to human C3c, thus detecting iC3b/C3c but not C3dg [19] . Thus the true assessment of deposition of complement fragments is actually missed by routine immunofluorescence studies.
It is interesting to note that although C3GN and DDD have differences at the electron microscopic level and that biomarker profiling supports a difference in the relative degree of alternative and terminal pathway activity in these two subtypes of C3G, their C3 proteomic profiles were very similar. While this similarity may mean that the distinction between C3GN and DDD is artificial, there are several limitations to this study that preclude this conclusion, including small study size, insufficient distribution of patients across the clinical disease spectra and lack of associated functional and biomarker complement data. Nevertheless, from this study it is clear that C3G is a dynamic disease in which bound C3b undergoes cleavage to smaller protein fragments with the eventual accumulation of C3dg, which accounts for the majority of the detected C3. Given this finding, it would appear that immunofluorescence in the detection of C3 is limited and when possible efforts should focus on comparing the relative intensity of staining for C3b and C3dg to determine whether this ratio correlates with disease activity.
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